Question follow-through · 77607

Life Sciences

To ask the Secretary of State for Science, Innovation and Technology, when she plans to publish the 2025 UK Life Sciences Competitiveness Indicators.

answeredDepartment for Science, Innovation and Technology

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department for Science, Innovation and Technology
Tabled
16 Sept 2025
Target answer date
13 Oct 2025
Answer
15 Oct 2025 · 29 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

Recorded timeline

  1. 16 Sept 2025

    Question tabled

    To ask the Secretary of State for Science, Innovation and Technology, when she plans to publish the 2025 UK Life Sciences Competitiveness Indicators.

  2. 13 Oct 2025

    Target answer date

    Date supplied by the official written-questions record.

  3. 15 Oct 2025

    Answer published

    The Office for Life Sciences will publicly announce the planned publication date of the Life Sciences Competitiveness Indicators one month in advance of its publication.

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Strong linkSame MP, department and exact heading

Life Sciences

10 Oct 2025 · To ask the Secretary of State for Science, Innovation and Technology, when she expects the Life Sciences Competitiveness Indicators 2025 report to be published.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

NHS: Drugs

10 Nov 2025 · To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking with the Secretary of State for Health and Social Care to ensure that funding for newly licensed medicines results in improved patient outcomes.